DE602006012487D1 - Tumorbehandlung mit gliotoxin-derivaten - Google Patents

Tumorbehandlung mit gliotoxin-derivaten

Info

Publication number
DE602006012487D1
DE602006012487D1 DE602006012487T DE602006012487T DE602006012487D1 DE 602006012487 D1 DE602006012487 D1 DE 602006012487D1 DE 602006012487 T DE602006012487 T DE 602006012487T DE 602006012487 T DE602006012487 T DE 602006012487T DE 602006012487 D1 DE602006012487 D1 DE 602006012487D1
Authority
DE
Germany
Prior art keywords
tumor treatment
gliotoxin
derivatives
gliotoxin derivatives
tumours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006012487T
Other languages
English (en)
Inventor
Rainer Hubmann
Wolfgang Sieghart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Universitaet Wien
Original Assignee
Medizinische Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Wien filed Critical Medizinische Universitaet Wien
Publication of DE602006012487D1 publication Critical patent/DE602006012487D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE602006012487T 2005-06-21 2006-06-21 Tumorbehandlung mit gliotoxin-derivaten Active DE602006012487D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0104405A AT502055B1 (de) 2005-06-21 2005-06-21 Anti tumor medikament
PCT/AT2006/000253 WO2006135949A2 (en) 2005-06-21 2006-06-21 Tumour treatment with gliotoxin derivatives

Publications (1)

Publication Number Publication Date
DE602006012487D1 true DE602006012487D1 (de) 2010-04-08

Family

ID=37102560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006012487T Active DE602006012487D1 (de) 2005-06-21 2006-06-21 Tumorbehandlung mit gliotoxin-derivaten

Country Status (7)

Country Link
US (1) US7981878B2 (de)
EP (1) EP1901750B1 (de)
AT (2) AT502055B1 (de)
AU (1) AU2006261566A1 (de)
CA (1) CA2612770A1 (de)
DE (1) DE602006012487D1 (de)
WO (1) WO2006135949A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717222A (zh) * 2011-02-24 2014-04-09 浙江大学 桥二硫二氧代哌嗪及其在治疗癌症方面的用途
WO2012177647A2 (en) 2011-06-20 2012-12-27 Kerry Lane Mycotoxin diagnostics and methods thereof
MX2014004074A (es) * 2011-10-05 2014-06-05 Genentech Inc Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
US9765090B2 (en) 2011-11-25 2017-09-19 Ewha University-Industry Collaboration Foundation Epidithiodioxopiperazine compound or its derivatives, and the use thereof
MX357675B (es) 2012-08-13 2018-07-18 Genentech Inc Anticuerpos anti-jagged y métodos de uso.
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
BR112015020290A2 (pt) 2013-03-15 2017-10-10 Genentech Inc métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
WO2014189343A1 (en) * 2013-05-24 2014-11-27 Ewha University - Industry Collaboration Foundation Epidithiodioxopiperazine compound or its derivatives, and the use thereof
CR20160362A (es) 2014-02-12 2016-09-20 Genentech Inc Anticuerpos anti-jagged1 y metodos de uso
EP3282019A1 (de) 2016-08-09 2018-02-14 Medizinische Universität Wien Genotypisierung und behandlung von krebs, insbesondere chronischer lymphozytischer leukämie
WO2019009646A1 (ko) * 2017-07-05 2019-01-10 바스테라 주식회사 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
CN114641294A (zh) * 2019-08-28 2022-06-17 瓦西特拉有限公司 用于预防或治疗实体癌的含有桥二硫二氧代哌嗪衍生物或其药学上可接受的盐的药物组合物
CN116286897B (zh) * 2023-03-29 2024-05-03 佛山科学技术学院 一种编码酰基转移酶的Tri3基因及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
JPS61277617A (ja) 1985-05-31 1986-12-08 Yakult Honsha Co Ltd 坑血小板凝集剤
WO1992010198A1 (en) * 1990-12-06 1992-06-25 Johnson & Johnson Research Pty Limited Immunotherapeutic agents, compositions and methods
JP2801491B2 (ja) 1993-01-26 1998-09-21 敦 沼田 エピポリチオジオキソピペラジン誘導体およびその製造法
JP3498925B2 (ja) 1994-02-18 2004-02-23 日本肥糧株式会社 グリオクラディウム・ビレンスによるグリオトキシンの生産方法
KR19990082168A (ko) * 1996-12-02 1999-11-25 에가시라 구니오 글리오톡신 유도체 및 이를 함유하는 항암제
US6703221B1 (en) * 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
US20040101847A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
AU2003249382A1 (en) 2002-06-26 2004-01-19 Pharmablood Inc. A method and composition to elicit an effective autologous antitumoral immune response in a patient
US20050191302A1 (en) 2002-08-29 2005-09-01 University Of Southampton Treatment for liver disease

Also Published As

Publication number Publication date
AT502055B1 (de) 2007-11-15
US20090029974A1 (en) 2009-01-29
ATE458487T1 (de) 2010-03-15
EP1901750B1 (de) 2010-02-24
EP1901750A2 (de) 2008-03-26
WO2006135949A3 (en) 2007-07-05
US7981878B2 (en) 2011-07-19
AT502055A1 (de) 2007-01-15
WO2006135949A2 (en) 2006-12-28
CA2612770A1 (en) 2006-12-28
AU2006261566A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TW200801006A (en) Fused bicyclic mTOR inhibitors
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
TW200738725A (en) Unsaturated mTOR inhibitors
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
EA200801425A1 (ru) Диазепиноны
EA201170344A1 (ru) Азаиндольные ингибиторы iap

Legal Events

Date Code Title Description
8364 No opposition during term of opposition